Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Cash from Financing Activities: 2017-2025

Historic Cash from Financing Activities for Cidara Therapeutics (CDTX) over the last 8 years, with Sep 2025 value amounting to $160,000.

  • Cidara Therapeutics' Cash from Financing Activities rose 187.91% to $160,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $481.8 million, marking a year-over-year increase of 101.72%. This contributed to the annual value of $337.1 million for FY2024, which is 1197.19% up from last year.
  • Latest data reveals that Cidara Therapeutics reported Cash from Financing Activities of $160,000 as of Q3 2025, which was down 99.96% from $383.4 million recorded in Q2 2025.
  • In the past 5 years, Cidara Therapeutics' Cash from Financing Activities ranged from a high of $383.4 million in Q2 2025 and a low of -$1.1 million during Q2 2022.
  • In the last 3 years, Cidara Therapeutics' Cash from Financing Activities had a median value of $118,500 in 2025 and averaged $74.7 million.
  • Per our database at Business Quant, Cidara Therapeutics' Cash from Financing Activities tumbled by 225.25% in 2022 and then surged by 1,227,462.50% in 2024.
  • Quarterly analysis of 5 years shows Cidara Therapeutics' Cash from Financing Activities stood at $36.9 million in 2021, then tumbled by 98.20% to $664,000 in 2022, then plummeted by 98.80% to $8,000 in 2023, then surged by 1,227,462.50% to $98.2 million in 2024, then spiked by 187.91% to $160,000 in 2025.
  • Its Cash from Financing Activities was $160,000 in Q3 2025, compared to $383.4 million in Q2 2025 and $77,000 in Q1 2025.